Form 4: Corcept Therapeutics President Sells Shares
Insider Transaction (Form 4)
Roberto Wandenkolk Vieira, President, Oncology of Corcept Therapeutics Inc, sold 58,333 shares of common stock on September 1, 2026.
Summary
- Grant/award: acquired 138 Common Stock at $113.38 ($15,646) on September 1, 2026; holds 4,206 after (Direct).
- Grant/award: acquired 138 Common Stock on September 1, 2026; holds 4,344 after (Direct).
- Tax/exercise-price withholding: disposed of 102 Common Stock at $113.38 ($11,565) on September 2, 2026; holds 4,242 after (Direct).
- Option exercise/conversion: acquired 58,333 Common Stock at $21.63 ($1,261,743) on September 2, 2026; holds 62,575 after (Direct).
- Open-market sale: disposed of 23,600 Common Stock at $109.35 ($2,580,674) on September 2, 2026; holds 38,975 after (Direct).
- Open-market sale: disposed of 23,770 Common Stock at $110.70 ($2,631,349) on September 2, 2026; holds 15,205 after (Direct).
- Open-market sale: disposed of 1,537 Common Stock at $111.37 ($171,181) on September 2, 2026; holds 13,668 after (Direct).
- Open-market sale: disposed of 974 Common Stock at $112.40 ($109,474) on September 2, 2026; holds 12,694 after (Direct).
- Open-market sale: disposed of 1,606 Common Stock at $113.72 ($182,632) on September 2, 2026; holds 11,088 after (Direct).
- Open-market sale: disposed of 5,621 Common Stock at $114.58 ($644,042) on September 2, 2026; holds 5,467 after (Direct).
- Open-market sale: disposed of 1,225 Common Stock at $115.44 ($141,413) on September 2, 2026; holds 4,242 after (Direct).
- Option exercise/conversion: disposed of 58,333 Stock option (right to buy) on September 2, 2026; holds 141,667 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $6,460,766 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Roberto Wandenkolk Vieira — Officer (President, Oncology)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-01 | Grant/award | Common Stock | 138 | $113 | $15.6K | 4,206 |
| 2026-09-01 | Grant/award | Common Stock | 138 | — | — | 4,344 |
| 2026-09-02 | Tax/exercise-price withholding | Common Stock | 102 | $113 | $11.6K | 4,242 |
| 2026-09-02 | Option exercise/conversion | Common Stock | 58,333 | $22 | $1.3M | 62,575 |
| 2026-09-02 | Open-market sale | Common Stock | 23,600 | $109 | $2.6M | 38,975 |
| 2026-09-02 | Open-market sale | Common Stock | 23,770 | $111 | $2.6M | 15,205 |
| 2026-09-02 | Open-market sale | Common Stock | 1,537 | $111 | $171.2K | 13,668 |
| 2026-09-02 | Open-market sale | Common Stock | 974 | $112 | $109.5K | 12,694 |
| 2026-09-02 | Open-market sale | Common Stock | 1,606 | $114 | $182.6K | 11,088 |
| 2026-09-02 | Open-market sale | Common Stock | 5,621 | $115 | $644.0K | 5,467 |
| 2026-09-02 | Open-market sale | Common Stock | 1,225 | $115 | $141.4K | 4,242 |
| 2026-09-02 | Option exercise/conversion | Stock option (right to buy) | 58,333 | — | — | 141,667 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-01 | Grant/award (138 shares) |
| 2026-09-01 | Grant/award (138 shares) |
| 2026-09-02 | Tax/exercise-price withholding (102 shares) |
| 2026-09-02 | Option exercise/conversion (58,333 shares) |
| 2026-09-02 | Open-market sale (23,600 shares) |
| 2026-09-02 | Open-market sale (23,770 shares) |
| 2026-09-02 | Open-market sale (1,537 shares) |
| 2026-09-02 | Open-market sale (974 shares) |
| 2026-09-02 | Open-market sale (1,606 shares) |
| 2026-09-02 | Open-market sale (5,621 shares) |
| 2026-09-02 | Open-market sale (1,225 shares) |
| 2026-09-02 | Option exercise/conversion (58,333 shares) |
Keywords
insider transaction, Form 4, CORT, CORCEPT THERAPEUTICS INC, bearish, Roberto Wandenkolk Vieira
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.